Clinical Trial

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-17
critical Recruitment opened 2026-04-21
Trial Details
NCT Number NCT07476118
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 150 participants
Start Date 2026-03-18
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-16